Are you Dr. Yu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
50 N Medical Dr
Salt Lake City, UT 84132Phone+1 801-581-2121
Summary
- Dr. Margaret Yu, MD is an oncologist in Salt Lake City, Utah. She is currently licensed to practice medicine in Utah and California.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2000 - 2003- University of Utah HealthResidency, Internal Medicine, 1997 - 2000
Medical College of WisconsinClass of 1997
Certifications & Licensure
CA State Medical License 2016 - 2025
UT State Medical License 1998 - 2018
Publications & Presentations
PubMed
- 22 citationsAssociation of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.Felix Y. Feng, Shibu Thomas, Fred Saad, Michael Gormley, Margaret K. Yu
JAMA Oncology. 2021-07-01 - 7 citationsBlood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as Th...Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos
Clinical Cancer Research. 2021-06-10 - 5 citationsImpact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.Arpit Rao, Howard I. Scher, Peter De Porre, Margaret K. Yu, Anil Londhe
ESMO Open. 2020-11-01
Press Mentions
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)December 19th, 2019
Erleada Cuts Risk of Death by 25% in Localized Castration-Resistant Prostate Cancer, Phase 3 Trial FindsOctober 2nd, 2019
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)September 27th, 2019- Join now to see all
